Current medical treatment of pancreatic neuroendocrine tumors

Hepato-Gastroenterology

Volumn 54, Issue 73, 2007, Pages 278-284

  Yalcin, Suayib ^a   Oyan, Basak ^b   Bayraktar, Yusuf ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Interferon; Neuroendocrine tumors; Pancreatic; Radiolabelled; Somatostatin analog

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LANTREOTIDE; LANTREOTIDE Y 90; LOMUSTINE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TAXANE DERIVATIVE; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ANORCHIA; BLOOD TOXICITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; GALLSTONE FORMATION; HEART ARRHYTHMIA; HUMAN; ILEUM DISEASE; LEUKOPENIA; LIVER LEVEL; MONOTHERAPY; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEATORRHEA; THROMBOCYTOPENIA; TUMOR CLASSIFICATION; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANGIOGENESIS INHIBITORS; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CYTOTOXINS; HUMANS; INTERFERON-ALPHA; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 34047150709     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Torre SD, Procopio G, Fusi A, et al: Current treatments of neuroendocrine tumors: role of biotherapy and chemotherapy. Tumori 2003; 89:111-116.
2. Solcia E, Kloppel G, Sobin LH: Histologic typing of endocrine tumours. WHO International Classification of Tumours, Springer Verlag, Heidelberg, 2000.
3. Shebani KO, Souba WW, Finkelstein DM, et al: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999; 229:815-823.
4. Aparicio T, Ducreux M, Baudin E, et al: Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Can 2001; 37:1014-1019.
5. Rubin J, Antonuzzo A, Galli L, et al: Octreotide acetate long-acting formulation versus open-label sc octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 88:600-606.
6. Ruszniewski P, Docreux M, Chayvialle JA, et al: Treatment of carcinoid syndrome with long-acting somatostatin analogue lantreotide: a prospective study in 39 patients. Gut 1996; 39:279-283.
7. Ricci S, Antonuzzo A, Galli L, et al: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lantreotide. Ann Oncol 2000; 11:1127-1130.
8. Öberg K: Established clinical use of octreotide and lantreotide in oncology. Chemotherapy 2001; 47(Suppl 2):40-53.
9. Öberg K: Interferon in the management of neuroendocrine GEP tumours. Dig 2000; 62(Suppl 1):92-97.
10. Frank M, Klose KJ, Wied M, et al: Combination therapy with octreotide and alfa interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94:1381-1387.
11. Faiss S, Pape UF, Böhmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lantreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lantreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696.
12. Fjallskog ML, Sundin A, Westlin JE, et al: Treatment of malignant endocrine pancreatic tumours with combination of alpha-interferon and somatostatin analogs. Med Oncol 2002; 19:35-42.
13. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variance of these neoplasms. Cancer 1991; 68:227-232.
14. Moertel CG, Hanley JA, Johnsson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Eng J Med 1980; 303:1189-1194.
15. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin- doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519-523.
16. Rivera E, Ajani JA: Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998; 21:36-38.
17. Bukowski RM, Tangen C, Lee R, et al: Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1914-1918.
18. Rougier P, Oliveira J, Ducreux M, et al: Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 1991; 27:1380-1382.
19. Kaltsas GA, Mukherjee JJ, Isidori A, et al: Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 2002; 57:169-183.
20. Mitry E, Baudin E, Ducreux M, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351-1355.
21. Mekhjian HS, O'Dorosio TM: VIPoma syndrome. Semin Oncol 1987; 14:282-291.
22. Friesen SR: Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987; 67:379-393.
23. Kulke MH, Ryan DP, Enzinger PC, et al: Phase II study of gemcitabine in patients with metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2001; 20:145b (abstr 2330).
24. Ansell SM, Pitot HC, Burch PA, et al: Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematological toxicity. Proc Am Soc Clin Oncol 2001; 20:138b (abstr 2302).
25. Ansell SM, Pitot HC, Burch PA, et al: A phase II study of high dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91:1543-1548.
26. Hou Z, Elasmar SA, Lozano R, et al: A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 2003; 22:378a (abstr 1508).
27. Catena L, Bajetta E, Procopio G, et al: Oxaliplatin plus capecitabine in advanced neuroendocrine tumors (NETs): is the new WHO classification applicable to daily practice. Eur J Cancer Supplements 2003; 1(5):S40.
28. Shah MH, Martin E, Ellison C, et al: A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002; 21:29a (abstr 111).
29. Kulke M, Bergsland E, Ryan DP, et al: A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol 2003; 22:240a (abstr 958).
30. Xu Y, Ellison C, Martin E, et al: A phase II study of thalidomide in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002; 21:45b (abstr 1931).
31. Ajani JA, Carrasco CH, Charnsangavej C, et al: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988; 108:340-344.
32. Ruszniewski P, Rougier P, Roche A, et al: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624-2630.
33. Clouse ME, Perry L, Stuart K, Stokes KR: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994; 55(Suppl 3):92-97.
34. Diaco DS, Hajarizadeh H, Mueller CR, et al: Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995; 169:523-528.
35. Dominguez S, Denys A, Madeira I, et al: Hepatic arterial chemoembolization with streptozocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000; 12:151-157.
36. Yao KA, Talamonti MS, Nemcek A, et al: Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130:677-682.
37. De Herder WW, Lamberts SWJ: Somatostatin and Somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14:53-57.
38. Smith MC, Liu J, Chen T, et al: OctreoTher: ongoing early clinical development of a somatostatin-receptor targeted radionucleotide antineoplastic therapy. Digestion 2000; 62(Suppl 1):69-71.
39. Anthony LB, Woltering EA, Espean GD, et al: Indium-111-pentreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123-132.
40. de Jong M, Valkema R, Jamar F, et al: Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
41. de Jong M, Breeman WA, Bernard BF, et al: Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999; 43:356-366.